Brief: Quantum Genomics receives regulatory approval to start phase II trial in hypertension
Nov 17 (Reuters) - Quantum Genomics SA ALQGC.PA :
* Receives all regulatory approvals to start its phase II
clinical trial in hypertension
Source text for Eikon: ID:nACT37990
Further company coverage: ALQGC.PA
(Gdynia Newsroom: +48 58 698 39 20)
((Gdynia.newsroom@thomsonreuters.com;))
Keywords: QUANTUMGENOMICSSA/BRIEF
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study